List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1781550/publications.pdf Version: 2024-02-01

		159585	110387
119	4,621	30	64
papers	citations	h-index	g-index
123	123	123	5850
all docs	docs citations	times ranked	citing authors

ROD S PASSMAN

#	Article	IF	CITATIONS
1	Inter-Patient Atrial Flutter Classification Using FFT-Based Features and a Low-Variance Stacking Classifier. IEEE Transactions on Biomedical Engineering, 2022, 69, 156-164.	4.2	4
2	Mobile Health for Arrhythmia Diagnosis and Management. Journal of General Internal Medicine, 2022, 37, 188-197.	2.6	14
3	Mobile health technologies in the diagnosis and management of atrial fibrillation. Current Opinion in Cardiology, 2022, 37, 1-9.	1.8	7
4	The 30-day readmission rate of same-day discharge protocol following catheter ablation for atrial fibrillation: a propensity score-matched analysis from National Readmission Database. Europace, 2022, 24, 755-761.	1.7	13
5	The future of longâ€ŧerm monitoring after catheter and surgical ablation for atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2022, 33, 1911-1918.	1.7	4
6	Updated USPSTF Guidelines for Screening for Atrial Fibrillation. JAMA Cardiology, 2022, , .	6.1	1
7	Randomized evaluation of decision support interventions for atrial fibrillation: Rationale and design of the RED-AF study. American Heart Journal, 2022, 248, 42-52.	2.7	6
8	Safety of MRI in patients with retained cardiac leads. Magnetic Resonance in Medicine, 2022, 87, 2464-2480.	3.0	11
9	Improvement in renal function following cryoballoon ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 513-520.	1.3	3
10	Evaluation of image quality of wideband singleâ€shot late gadoliniumâ€enhancement MRI in patients with a cardiac implantable electronic device. Journal of Cardiovascular Electrophysiology, 2021, 32, 138-147.	1.7	3
11	2021 ISHNE/ HRS/ EHRA/ APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. Annals of Noninvasive Electrocardiology, 2021, 26, e12795.	1.1	29
12	Using 5D flow MRI to decode the effects of rhythm on left atrial 3D flow dynamics in patients with atrial fibrillation. Magnetic Resonance in Medicine, 2021, 85, 3125-3139.	3.0	14
13	2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society. Circulation: Arrhythmia and Electrophysiology. 2021, 14, e009204.	4.8	45
14	2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. Cardiovascular Digital Health Journal, 2021, 2, 4-54.	1.3	10
15	A Case of Rapidly Progressing Granulomatous Myocarditis. Circulation: Heart Failure, 2021, 14, e007800.	3.9	2
16	Cardiovascular Risk Factors in Young Adolescents: Results from the National Health and Nutrition Examination Survey 1988–2016. Southern Medical Journal, 2021, 114, 261-265.	0.7	3
17	"Pill-in-Pocket―Anticoagulation for Atrial Fibrillation: Fiction, Fact, or Foolish?. Circulation, 2021, 143, 2211-2213.	1.6	14
18	Impact of preâ€ablation weight loss on the success of catheter ablation for atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2021, 32, 2097-2104.	1.7	10

ROD S PASSMAN

#	Article	IF	CITATIONS
19	Association of Lower Urinary Tract Symptoms Based on the International Prostate Symptom Score and Cardiovascular Disease. Circulation Journal, 2021, 85, 2092-2099.	1.6	4
20	Atrial fibrillation and atrial cardiomyopathies. Journal of Cardiovascular Electrophysiology, 2021, 32, 2845-2853.	1.7	5
21	Reexamination of the Embolic Stroke of Undetermined Source Concept. Stroke, 2021, 52, 2715-2722.	2.0	9
22	HRS White Paper on Clinical Utilization of Digital Health Technology. Cardiovascular Digital Health Journal, 2021, 2, 196-211.	1.3	9
23	Trends in Cardiovascular Mortality Related to Atrial Fibrillation in the United States, 2011 to 2018. Journal of the American Heart Association, 2021, 10, e020163.	3.7	49
24	Use of Smartphones and Wearables for Arrhythmia Monitoring. Cardiac Electrophysiology Clinics, 2021, 13, 509-522.	1.7	2
25	Use of a novel 4D intracardiac echocardiography catheter to guide interventional electrophysiology procedures. Journal of Cardiovascular Electrophysiology, 2021, 32, 3117-3124.	1.7	10
26	Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke. JAMA Cardiology, 2021, 6, 1364.	6.1	47
27	2021 ISHNE / HRS / EHRA / APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. European Heart Journal Digital Health, 2021, 2, 7-48.	1.7	4
28	The future of longâ€ŧerm monitoring following catheter and surgical intervention for atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2021, 32, 2808-2812.	1.7	3
29	Shared Decision Making in Cardiac Electrophysiology Procedures and Arrhythmia Management. Circulation: Arrhythmia and Electrophysiology, 2021, 14, CIRCEP121007958.	4.8	20
30	Characterization of atrial flutter after pulmonary vein isolation by cryoballoon ablation. Journal of Interventional Cardiac Electrophysiology, 2020, 57, 233-240.	1.3	3
31	A novel risk model for very late return of atrial fibrillation beyond 1Âyear after cryoballoon ablation: the SCALE-CryoAF score. Journal of Interventional Cardiac Electrophysiology, 2020, 58, 209-217.	1.3	13
32	External validity of a model to predict postoperative atrial fibrillation after thoracic surgery. European Journal of Cardio-thoracic Surgery, 2020, 57, 874-880.	1.4	11
33	Left ventricular extracellular volume expansion does not predict recurrence of atrial fibrillation following catheter ablation. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 159-166.	1.2	2
34	Digital Health and the Care of the Patient With Arrhythmia. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007953.	4.8	20
35	Use of Oral Anticoagulation in a Realâ€World Population With Device Detected Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e018378.	3.7	4
36	Attenuation of Oxidative Injury With Targeted Expression of NADPH Oxidase 2 Short Hairpin RNA Prevents Onset and Maintenance of Electrical Remodeling in the Canine Atrium. Circulation, 2020, 142, 1261-1278.	1.6	21

#	Article	IF	CITATIONS
37	Atrial fibrillation ablation success defined by duration of recurrence on cardiac implantable electronic devices. Journal of Cardiovascular Electrophysiology, 2020, 31, 3124-3131.	1.7	9
38	Efficacy and Safety of Direct Oral Anticoagulants for Atrial Fibrillation Across Body Mass Index Categories. Journal of the American Heart Association, 2020, 9, e017383.	3.7	13
39	Left Ventricular Extracellular Volume Expansion Is Not Associated with Atrial Fibrillation or Atrial Fibrillation–mediated Left Ventricular Systolic Dysfunction. Radiology: Cardiothoracic Imaging, 2020, 2, e190096.	2.5	2
40	Accelerated 3D Left Atrial Late Gadolinium Enhancement in Patients with Atrial Fibrillation at 1.5 T: Technical Development. Radiology: Cardiothoracic Imaging, 2020, 2, e200134.	2.5	5
41	Patientâ€reported outcomes after cryoballoon ablation are equivalent between moderate sedation and general anesthesia. Journal of Cardiovascular Electrophysiology, 2020, 31, 1579-1584.	1.7	10
42	Response by Kaplan et al to Letter Regarding Article, "Stroke Risk as a Function of Atrial Fibrillation Duration and CHA 2 DS 2 -VASc Score― Circulation, 2020, 141, e599-e600.	1.6	0
43	Repeat pulmonary vein isolation with or without FIRMâ€guided ablation for recurrent atrial fibrillation with pulmonary vein reconnection. Journal of Cardiovascular Electrophysiology, 2020, 31, 1031-1037.	1.7	9
44	Artificial Intelligence and Machine Learning in Arrhythmias and Cardiac Electrophysiology. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007952.	4.8	96
45	Embarking upon atrial fibrillation management in heart failure with preserved ejection fraction: Charting a course. Journal of Cardiovascular Electrophysiology, 2020, 31, 2284-2287.	1.7	1
46	Racial Disparity in the Prescription of Anticoagulants and Risk of Stroke and Bleeding in Atrial Fibrillation Patients. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104718.	1.6	22
47	Association of the H ₂ FPEF Risk Score with Recurrence of Atrial Fibrillation Following Pulmonary Vein Isolation. Journal of Atrial Fibrillation, 2020, 12, 2295.	0.5	4
48	Changes in the specific absorption rate (SAR) of radiofrequency energy in patients with retained cardiac leads during MRI at 1.5T and 3T. Magnetic Resonance in Medicine, 2019, 81, 653-669.	3.0	42
49	Stroke Risk as a Function of Atrial Fibrillation Duration and CHA ₂ DS ₂ -VASc Score. Circulation, 2019, 140, 1639-1646.	1.6	178
50	Transparent sharing of digital health data: A call to action. Heart Rhythm, 2019, 16, e95-e106.	0.7	24
51	Defibrillators Don't Deliver in Dialysis. Circulation, 2019, 139, 2639-2641.	1.6	3
52	Smartwatch Performance for the Detection and Quantification of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006834.	4.8	163
53	Evaluation of a clinical score for predicting atrial fibrillation in cryptogenic stroke patients with insertable cardiac monitors: results from the CRYSTAL AF study. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984269.	3.5	24
54	Patient characteristics as predictors of recurrence of atrial fibrillation following cryoballoon ablation. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 694-704.	1.2	24

#	Article	IF	CITATIONS
55	Discriminative Ability of CHA2DS2-VASc and HAS-BLED Score in Whites and Nonwhites. American Journal of Cardiology, 2019, 123, 1949-1954.	1.6	0
56	Keeping a finger on the pulse of atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2019, 30, 639-641.	1.7	0
57	Incidence of atrial fibrillation among patients with an embolic stroke of undetermined source: Insights from insertable cardiac monitors. International Journal of Stroke, 2019, 14, 146-153.	5.9	25
58	Region-specific parasympathetic nerve remodeling in the left atrium contributes to creation of a vulnerable substrate for atrial fibrillation. JCI Insight, 2019, 4, .	5.0	18
59	Is a little atrial fibrillation still too much?. Heart Rhythm, 2018, 15, 812-813.	0.7	1
60	When is Device-Detected Atrial Fibrillation Actionable?. Cardiac Electrophysiology Clinics, 2018, 10, 75-85.	1.7	2
61	Atrial fibrillation and stroke: The more we learn, the less we understand. American Heart Journal, 2018, 201, 158-159.	2.7	3
62	Dialytic interval and the timing of electrocardiographic screening for subcutaneous cardioverter-defibrillator placement in chronic hemodialysis patients. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 179-184.	1.3	5
63	Quality of life in patients with implantable cardioverter–defibrillator: systematic review of randomized controlled trials. European Journal of Cardiovascular Nursing, 2018, 17, 196-206.	0.9	27
64	Contribution of symmetric dimethylarginine to GFR decline in pediatric chronic kidney disease. Pediatric Nephrology, 2018, 33, 697-704.	1.7	4
65	Conduction recovery following pacemaker implantation after transcatheter aortic valve replacement. PACE - Pacing and Clinical Electrophysiology, 2018, 42, 146-152.	1.2	28
66	The Current Landscape of AtrialÂFibrillation and Atrial Flutter ClinicalÂTrials. JACC: Clinical Electrophysiology, 2018, 4, 944-954.	3.2	5
67	Electrocardiography Screening for Atrial Fibrillation. JAMA Cardiology, 2018, 3, 1144.	6.1	6
68	Intermittent anticoagulation guided by continuous atrial fibrillation burden monitoring using dual-chamber pacemakers and implantable cardioverter-defibrillators: Results from the Tailored Anticoagulation for Non-Continuous Atrial Fibrillation (TACTIC-AF) pilot study. Heart Rhythm, 2018, 15, 1601-1607.	0.7	37
69	Outcomes With Novel Oral Anticoagulants in Obese Patients who Underwent Electrical Cardioversion for Atrial Tachyarrhythmias. American Journal of Cardiology, 2018, 122, 1175-1178.	1.6	6
70	Oxidative stress creates a unique, CaMKII-mediated substrate for atrial fibrillation in heart failure. JCI Insight, 2018, 3, .	5.0	50
71	Cryptogenic Stroke. Circulation Research, 2017, 120, 527-540.	4.5	141
72	Development and validation of a dual sensing scheme to improve accuracy of bradycardia and pause detection in an insertable cardiac monitor. Heart Rhythm, 2017, 14, 1016-1023.	0.7	16

ROD S PASSMAN

#	Article	IF	CITATIONS
73	Bronchial effects of cryoballoon ablation for atrial fibrillation. Heart Rhythm, 2017, 14, 12-16.	0.7	31
74	Atrial fibrillation variability on longâ€ŧerm monitoring of implantable cardiac rhythm management devices. Clinical Cardiology, 2017, 40, 1044-1048.	1.8	3
75	Can Implantable Cardiac Devices Be Used to Lower Risk of Stroke?. Current Cardiovascular Risk Reports, 2017, 11, 1.	2.0	0
76	Monitoring for AF: Identifying the Burden of Atrial Fibrillation and Assessing Post-Ablation. Journal of Innovations in Cardiac Rhythm Management, 2017, 8, 2575-2582.	0.5	6
77	Reconnection Rate and Long-Term Outcome with Adenosine Provocation During Cryoballoon Ablation for Pulmonary Vein Isolation. Journal of Atrial Fibrillation, 2017, 9, 1510.	0.5	1
78	Manifest Left Atrial Appendage Delay on a 12‣ead EKG After AF Ablation. Journal of Cardiovascular Electrophysiology, 2016, 27, 492-493.	1.7	0
79	Sex, Symptoms, and Atrial Fibrillation. JAMA Cardiology, 2016, 1, 292.	6.1	Ο
80	Real-world performance of an enhanced atrial fibrillation detection algorithm in an insertable cardiac monitor. Heart Rhythm, 2016, 13, 1624-1630.	0.7	72
81	Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015ÂDiagnostics and Monitoring Stroke Focus Group Report. Journal of the American Heart Association, 2016, 5, e002944.	3.7	37
82	Cardiac Monitoring for Atrial Fibrillation in Cryptogenic Stroke. Cardiology Clinics, 2016, 34, 287-297.	2.2	4
83	Cost Effectiveness of Implantable Cardiac Monitorâ€Guided Intermittent Anticoagulation for Atrial Fibrillation: An Analysis of the REACT.COM Pilot Study. Journal of Cardiovascular Electrophysiology, 2016, 27, 1304-1311.	1.7	8
84	The Safety of Cardiac and Thoracic Magnetic Resonance Imaging in Patients with Cardiac Implantable Electronic Devices. Academic Radiology, 2016, 23, 1498-1505.	2.5	35
85	Time in Therapeutic Range in Warfarin-Treated Patients. JAMA - Journal of the American Medical Association, 2016, 316, 872.	7.4	9
86	Moderate Sedation Reduces Lab Time Compared to General Anesthesia during Cryoballoon Ablation for AF Without Compromising Safety or Longâ€Term Efficacy. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1359-1365.	1.2	22
87	Tâ€Wave Alternans, Heart Rate Turbulence, and Ventricular Ectopy in Standard versus Daily Hemodialysis: Results from the FHN Daily Trial. Annals of Noninvasive Electrocardiology, 2016, 21, 566-571.	1.1	8
88	Constitutive Expression of a Dominant-Negative TGF-β Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate. Circulation Research, 2016, 119, 69-82.	4.5	44
89	Targeted Anticoagulation for Atrial Fibrillation Guided by Continuous Rhythm Assessment With an Insertable Cardiac Monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) Pilot Study. Journal of Cardiovascular Electrophysiology, 2016, 27, 264-270.	1.7	91
90	Gender differences in outcomes after surgical ablation of atrial fibrillation. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 391-398.e2.	0.8	16

#	Article	IF	CITATIONS
91	Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves. Clinical Research in Cardiology, 2016, 105, 268-272.	3.3	54
92	Clinical Significance of Nonsustained Ventricular Tachycardia on Routine Monitoring of Pacemaker Patients. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 980-988.	1.2	10
93	MRI Conditional Devices, Safety, and Access: Choose Wisely and When You Come to the Fork in the Road, Take It. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1373-1376.	1.2	7
94	Cryoballoon versus Radiofrequency Catheter Ablation for Paroxysmal Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 483-489.	1.2	65
95	Low Yield of Mobile Cardiac Outpatient Telemetry after Cryptogenic Stroke in Patients with Extensive Cardiac Imaging. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 2069-2073.	1.6	7
96	A Comparison of Atrial Fibrillation Monitoring Strategies After Cryptogenic Stroke (from the) Tj ETQq0 0 0 rgBT /	Overlock I	10 Tf 50 542 ⁻ 78
97	Management of Device-detected Atrial High-rate Episodes. Cardiac Electrophysiology Clinics, 2015, 7, 515-525.	1.7	9
98	Role of Atrial Fibrillation Burden in Assessing Thromboembolic Risk. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1223-1229.	4.8	23
99	Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous	0.7	99

	implantable cardioverter-defibrillator. Heart Rhythm, 2014, 11, 1361-1366.		
100	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm, 2014, 11, 925-932.	0.7	52
101	Electrogram morphology recurrence patterns during atrial fibrillation. Heart Rhythm, 2014, 11, 2027-2034.	0.7	59
102	Cryptogenic Stroke and Underlying Atrial Fibrillation. New England Journal of Medicine, 2014, 370, 2478-2486.	27.0	1,694
103	Relationship between repolarization heterogeneity and abnormal myocardial mechanics. International Journal of Cardiology, 2014, 172, 289-291.	1.7	18
104	Electrocardiographic Markers of Repolarization Heterogeneity During Dofetilide or Sotalol Initiation for Paroxysmal Atrial Fibrillation. American Journal of Cardiology, 2014, 113, 2030-2035.	1.6	3
105	The Impact of Early Detection of Atrial Fibrillation on Stroke Outcomes. Cardiac Electrophysiology Clinics, 2014, 6, 125-132.	1.7	Ο
106	Safety of Short-Term Use of Dabigatran or Rivaroxaban for Direct-Current Cardioversion in Patients With Atrial Fibrillation and Atrial Flutter. American Journal of Cardiology, 2014, 113, 1362-1363.	1.6	44
107	MY APPROACH to Detecting Atrial Fibrillation*. Trends in Cardiovascular Medicine, 2014, 24, 215.	4.9	Ο
108	Prevention of Sudden Cardiac Death in Dialysis Patients: Drugs, Defibrillators or What Else?. Blood	1.8	12

Purification, 2013, 35, 49-54.

#	Article	IF	CITATIONS
109	Predicting the Future. Circulation, 2012, 125, 3031-3037.	1.6	29
110	Amiodarone-associated Optic Neuropathy: A Critical Review. American Journal of Medicine, 2012, 125, 447-453.	1.5	64
111	The Effects of Rateâ€Adaptive Atrial Pacing Versus Ventricular Backup Pacing on Exercise Capacity in Patients with Left Ventricular Dysfunction. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1-6.	1.2	12
112	Implantable Cardioverter Defibrillators and Quality of Life <subtitle>Results From the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation Study</subtitle> . Archives of Internal Medicine, 2007, 167, 2226.	3.8	120
113	Sudden Death Prevention With Implantable Devices. Circulation, 2007, 116, 561-571.	1.6	45
114	Radiofrequency Ablation of Atrial Flutter:. A Randomized Controlled Trial of Two Anatomic Approaches. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 83-88.	1.2	17
115	Accuracy of Mode Switch Algorithms for Detection of Atrial Tachyarrhythmias. Journal of Cardiovascular Electrophysiology, 2004, 15, 773-777.	1.7	95
116	Clinical Spectrum and Prevalence of Neurologic Events Provoked by Tilt Table Testing. Archives of Internal Medicine, 2003, 163, 1945.	3.8	39
117	Atrioventricular Junction Ablation Performed via a Patent Foramen Ovale. Journal of Cardiovascular Electrophysiology, 2001, 12, 617-617.	1.7	0
118	Effects of Sex and Age on Electrocardiographic and Cardiac Electrophysiological Properties in Adults. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 16-21.	1.2	115
119	Polymorphic Ventricular Tachycardia. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 338-342.	1.0	1